Caffeine May Enhance NSAID-Induced Effects on Colon Cancer Cells

Oncology NEWS InternationalOncology NEWS International Vol 6 No 7
Volume 6
Issue 7

WASHINGTON--Laboratory studies from Rockefeller University, presented at Digestive Disease Week, suggest that caffeine may have a synergistic effect with NSAIDs in preventing the growth of cancer cells.

WASHINGTON--Laboratory studies from Rockefeller University, presentedat Digestive Disease Week, suggest that caffeine may have a synergisticeffect with NSAIDs in preventing the growth of cancer cells.

At a press briefing, Yael Goldberg, MD, said that laboratory tests haveshown that NSAIDs have an antiproliferative effect on colon cancer cellsas well as the capacity to interfere with the cell cycle and induce apoptosis.And among the cells that do not die, about 90% arrest in the cell cycle,she said.

Working in the laboratory of Dr. Steven Shiff, Dr. Goldberg and hercolleagues treated colon cancer cells with different agents in an attempt,she said, "to look more closely at the mechanism responsible for theantineoplastic effect of NSAIDs, and to think about practical ways to treatpatients."

The researcher treated HT-29 colon adenocarcinoma cells and U-2 OS osteosarcomacells for 72 hours with either a control medium alone or a control mediumsupplemented with indomethacin (400 µM), sulindac (1,200 µM),sulindac sulfide (175 µM), or caffeine (4 µM), or co-supplementedwith caffeine and one of each of the NSAIDs.

In both HT-29 and U-2 OS cells, caffeine treatment alone profoundlyinhibited proliferation but did not induce apoptosis.

Co-treatment with caffeine and one of the NSAIDs reduced proliferationmore than did treatment with any of the agents used alone. When used incombination, caffeine significantly enhanced NSAID-induced apoptosis, andalso altered cell cycle distribution and levels of several key proteinsthat likely modulate the NSAID-induced cell cycle arrest.

Related Videos
Experts on multiple myeloma
Experts on multiple myeloma
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
Experts on GVHD with a patient
Experts on breast cancer
Experts on GVHD with a patient
Experts on breast cancer
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Related Content